SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results for the third quarter ended September 30, 2007 and operational highlights.
"The third quarter of 2007 marked an important transition for Anadys," said Steve Worland, Ph.D., President and Chief Executive Officer of Anadys. "We elected to focus investment on our two product candidates we believe most likely to create value, ANA598 for hepatitis C virus infection and ANA773 in oncology. Concurrently, we discontinued development of ANA975 and ANA380 and ceased early discovery efforts."
"We decided to focus on ANA598 and ANA773 based on the demonstrated preclinical properties of these compounds and our anticipation of future clinical benefits," continued Dr. Worland. "We are pleased to announce today that our IND to commence clinical investigation of ANA773 has been accepted by the FDA and we look forward to initiating a trial in cancer patients by the end the year. In parallel, we continue to advance ANA598 through IND enabling studies. We believe that our decision to focus investment on these two product candidates will enable us to achieve meaningful clinical milestones in both programs with our existing cash reserves."
In the third quarter, the Company and its collaborator, Novartis,
decided to discontinue the development of ANA975, a Phase 1b compound for
the treatment of hepatitis C virus (HCV) infection. Also during the third
quarter, Novartis and Anadys concluded that no further activities will be
pursued under the c
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved